drugset / Trial / NCT00003819
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Phase 1
Completed
21 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
Timeline
- Start
- 1998-06
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TF(c)-KLH conjugate vaccine | Vaccine | — | Subcutaneous |
| Subject | Thomsen-Friedenreich antigen | Unknown | — | Subcutaneous |
| Subject | keyhole limpet hemocyanin | Vaccine | — | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |